Viewing Study NCT00415532

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:24 PM
Ignite Modification Date: 2026-06-13 @ 7:18 AM
Study NCT ID: NCT00415532
Status: COMPLETED
Last Update Posted: 2022-11-08
First Post: 2006-12-21
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Idiopathic Thrombocytopenic Purpura View
None Thrombocytopenia View
None Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) View
None Thrombocytopenic Purpura View
Keywords:

Keywords

Keyword Brief Keyword Text View
None splenectomy View
None platelet View
None AMG 531 View
None thrombopoietin View
None blood disorder View
None bleeding disorder View
None immune thrombocytopenic purpura View
None idiopathic thrombocytopenic purpura View
None immune (idiopathic) thrombocytopenic purpura View
None TPO View
None thrombopoietic protein View